BioCryst Pharmaceuticals, Inc. (BCRX)
8.17
+0.05
(+0.62%)
USD |
NASDAQ |
Oct 02, 16:00
8.15
-0.02
(-0.24%)
After-Hours: 20:00
BioCryst Pharmaceuticals Gross Profit Margin (Quarterly) : 98.01% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 98.01% |
| March 31, 2026 | 95.88% |
| December 31, 2025 | 97.56% |
| September 30, 2025 | 98.42% |
| June 30, 2025 | 98.09% |
| March 31, 2025 | 96.63% |
| December 31, 2024 | 95.10% |
| September 30, 2024 | 96.98% |
| June 30, 2024 | 98.12% |
| March 31, 2024 | 98.17% |
| December 31, 2023 | 97.79% |
| September 30, 2023 | 98.21% |
| June 30, 2023 | 98.36% |
| March 31, 2023 | 98.05% |
| December 31, 2022 | 96.36% |
| September 30, 2022 | 94.72% |
| June 30, 2022 | 99.11% |
| March 31, 2022 | 98.89% |
| December 31, 2021 | 98.75% |
| September 30, 2021 | 97.94% |
| June 30, 2021 | 98.92% |
| March 31, 2021 | 68.18% |
| December 31, 2020 | 93.50% |
| September 30, 2020 | 74.99% |
| June 30, 2020 | 0.00% |
| Date | Value |
|---|---|
| March 31, 2020 | 94.05% |
| December 31, 2019 | 93.53% |
| September 30, 2019 | 88.73% |
| June 30, 2019 | 85.70% |
| March 31, 2019 | 74.76% |
| December 31, 2018 | 92.60% |
| September 30, 2018 | 85.35% |
| June 30, 2018 | 98.06% |
| March 31, 2018 | 94.14% |
| December 31, 2017 | 94.34% |
| September 30, 2017 | 85.65% |
| June 30, 2017 | 93.74% |
| March 31, 2017 | 96.88% |
| December 31, 2016 | 72.70% |
| September 30, 2016 | 97.03% |
| June 30, 2016 | 97.58% |
| March 31, 2016 | 98.40% |
| December 31, 2015 | 98.92% |
| September 30, 2015 | 87.70% |
| June 30, 2015 | 98.29% |
| March 31, 2015 | 98.90% |
| December 31, 2014 | 99.19% |
| September 30, 2014 | 98.76% |
| June 30, 2014 | 96.66% |
| March 31, 2014 | 97.89% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Amgen, Inc. | 72.08% |
| Halozyme Therapeutics, Inc. | 77.40% |
| Neurocrine Biosciences, Inc. | 95.87% |
| Vertex Pharmaceuticals, Inc. | 85.37% |
| Agenus, Inc. | 98.50% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -78.80% |
| Return on Invested Capital | -116.1% |
| Profit Margin (Quarterly) | 35.92% |
| Operating Margin (Quarterly) | 45.12% |
| Return on Net Operating Assets | -300.6% |